Oncology
Oropharyngeal Carcinoma
6
Pipeline Programs↗
2
Active Trials↗
5
Companies Involved↗
Oropharyngeal Carcinoma is an early-stage landscape with 6 programs across 5 companies. The most active players are McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Regeneron, Roche.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 26
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
6programs
Small molecule350%
Monoclonal antibody350%
Modality classified for 100% of 6 pipeline programs.
Analysis
Trial Status
3
clinical trials
Active, not recruiting1 · 33%
Recruiting1 · 33%
Suspended1 · 33%
Clinical Trials
Trial Activity
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)